✦ LIBER ✦

Gemcitabine Reverses Cisplatin Resistance: Demonstration of Activity in Platinum- and Multidrug-Resistant Ovarian and Peritoneal Carcinoma

✍ Scribed by Peter G. Rose; Kim Mossbruger; Nancy Fusco; Mary Smrekar; Sue Eaton; Michael Rodriguez

Book ID: 112251998
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 99 KB
Volume: 88
Category: Article
ISSN: 0090-8258
DOI: 10.1006/gyno.2002.6850

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gemcitabine reverses platinum resistance

Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma

✍ P. G. Rose 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

Biweekly gemcitabine and cisplatin in pl

Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma

✍ George Bozas; Aristotle Bamias; Vassiliki Koutsoukou; Eleni Efstathiou; Dimitra 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 227 KB

Gemcitabine and cisplatin chemotherapy i

Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma

✍ Devansu Tewari; Bradley J. Monk; Mark Hunter; Camille A. Falkner; Robert A. Burg 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 110 KB

Gemcitabine and pegylated liposomal doxo

Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma

✍ Dimitrios Pectasides; Nicolaos Xiros; George Papaxoinis; Gerasimos Aravantinos; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Clinical Activity of Gemcitabine Plus Pe

Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

✍ Makhija, S.; Amler, L. C.; Glenn, D.; Ueland, F. R.; Gold, M. A.; Dizon, D. S.; 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 729 KB

Titanocendichloride activity in cisplati

Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines

✍ Harstrick, A.; Schmoll, H.-J.; Poliwoda, H.; Sass, G.; Rustum, Y. 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 297 KB